Compositions for classifying a human pediatric subject having adolescent idiopathic scoliosis (ais)

Abstract

A composition for classifying a human pediatric subject having adolescent idiopathic scoliosis (AIS), comprising (a) a cell sample of the subject; and (b) a known melatonin-signaling pathway agonist, wherein said melatonin signaling pathway in said cell sample has been artificially induced by said melatonin-signaling pathway agonist, wherein the cell sample is selected from the group consisting of blood cell sample, osteoblast cell sample, osteoclast cell sample and myoblast cell sample, and whereby the composition enables the detection of the presence or absence of at least one impairment in the melatonin-signaling pathway in cells from said cell sample and thereby enables the classification of subject.

1 . A composition for classifying a human pediatric subject having adolescent idiopathic scoliosis (AIS), comprising (a) a cell sample of the subject; and (b) a known melatonin-signaling pathway agonist, wherein said melatonin signaling pathway in said cell sample has been artificially induced by said melatonin-signaling pathway agonist, wherein the cell sample is selected from the group consisting of blood cell sample, osteoblast cell sample, osteoclast cell sample and myoblast cell sample, and whereby the composition enables the detection of the presence or absence of at least one impairment in the melatonin-signaling pathway in cells from said cell sample and thereby enables the classification of subject. 
     
     
         2 . The composition of  claim 1 , wherein said cell sample is a blood cell sample selected from the group consisting of lymphocyte cell sample and monocyte cell sample. 
     
     
         3 . The composition of  claim 1 , wherein said cell sample is a lymphocyte cell sample. 
     
     
         4 . The composition of  claim 1 , wherein said cell sample is a monocyte cell sample. 
     
     
         5 . The composition of  claim 1 , wherein said known melatonin-signaling pathway agonist is a melatonin analog. 
     
     
         6 . The composition of  claim 1 , wherein said known melatonin-signaling pathway agonist is melatonin. 
     
     
         7 . The composition of  claim 1 , wherein said known melatonin-signaling pathway agonist is a GTP analog. 
     
     
         8 . The composition of  claim 1 , wherein said known melatonin-signaling pathway agonist is GTP. 
     
     
         9 . The composition of  claim 1 , further comprising a known activator of adenylyl cyclase. 
     
     
         10 . The composition of  claim 9 , wherein said known activator of adenylyl cyclase is forskolin. 
     
     
         11 . The composition of  claim 1 , further comprising artificial bone or dentin matrix, wherein said sample is an osteoclast cell sample. 
     
     
         12 . The composition of  claim 1 , further comprising [ 3 H]-thymidine, wherein said cell sample is an osteoblast cell sample. 
     
     
         13 . A composition for classifying a human pediatric subject having idiopathic scoliosis (AIS), comprising (a) a lysed cell sample of the subject; and (b) reagents for detecting cAMP accumulation, wherein, prior to being lysed, said cell sample has been contacted with a known activator of adenylyl cyclase to artificially induce Cyclic Adenosine Monophosphate (cAMP) accumulation and subsequently with a known melatonin-signaling pathway agonist, wherein the cell sample is selected from the group consisting of blood cell sample, osteoblast cell sample, osteoclast cell sample and myoblast cell sample, and whereby the composition enables the detection of the presence or absence of at least one impairment in the melatonin-signaling pathway in cells from said cell sample and thereby enables the classification of the subject. 
     
     
         14 . The composition of  claim 13 , wherein said known activator of adenylyl cyclase is forskolin. 
     
     
         15 . The composition of  claim 13 , wherein said known melatonin-signaling pathway agonist is a melatonin analog. 
     
     
         16 . The composition of  claim 1 , wherein said known melatonin-signaling pathway agonist is melatonin. 
     
     
         17 . The composition of  claim 1 , wherein said known melatonin-signaling pathway agonist is a GTP analog. 
     
     
         18 . The composition of  claim 1 , wherein said known melatonin-signaling pathway agonist is GTP. 
     
     
         19 . The composition of  claim 1 , wherein said reagents for detecting cAMP comprises an antibody which binds to cAMP. 
     
     
         20 . The composition of  claim 1 , wherein said known melatonin-signaling pathway agonist is at a pharmacological concentration 
     
     
         21 . The composition of  claim 21 , wherein said cell sample has been contacted with a pharmacological concentration of said know melatonin-signaling pathway agonist. 
     
     
         22 . The composition of  claim 1 , further comprising an antibiotic.